December 4, 2019 07:26 AM EST
R&D

An old, con­tro­ver­sial Pfiz­er drug shows mid-stage ef­fi­ca­cy against nar­colep­sy

Jason Mast

Editor

Re­box­e­tine nev­er got much trac­tion in the US. Mar­ket­ed as an an­ti-de­pres­sant in Eu­rope for the past 20 years, the Pfiz­er drug was pro­vi­sion­al­ly FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times